Clear All
767 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Vandetanib Caprelsa 100 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Yes 2011 In Use
NA Estrogens, Conjugated Cenestin, Duavee, Enjuvia, Premarin, Premphase, Prempro Cenestin®, Duavee® (combination), Enjuvia®, Premarin®, Premarin® Intravenous, Premphase® (combination), Prempro® (combination) multiple Hormonal Therapy Estrogen Yes 1998 In Use
NA Thalidomide Thalomid 150 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Thalidomide Thalomid 50 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 1998 In Use
NA Lorlatinib Lorbrena 25mg, 100mg Chemotherapy Tyrosine Kinase Inhibitor ALK/ROS1 Yes 2018 In Use
NA Fluorouracil Carac, Efudex topical, varies Chemotherapy Antimetabolite Pyrimidine Analog No 1970 In Use
NA Panobinostat Farydak 20 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
NA Rucaparib Rubraca 250 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
NA Dasatinib Sprycel 20 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Selinexor Xpovio 20mg, 40mg, 50mg, 60mg Chemotherapy Enzyme Inhibitor XPO1 Yes 2019 In Use
NA Cedazuridine and Decitabine Inqovi 100mg, 35mg Chemotherapy Antimetabolite Pyrimidine Analog + CDA Inhibitor Yes 2020 In Use
NA Dasatinib Sprycel 140 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Cyclosporine NeOral 25mg, 100mg Ancillary Therapy Immunomodulator Calcineurin Inhibitor Yes 1995 In Use
NA Anagrelide Agrylin 0.5mg Ancillary Therapy Platelet-Reducing Agent PDE-3 Inhibitor Yes 1997 In Use
NA Regorafenib Stivarga 40 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET,TIE2,DDR2,TrkQ,RAF,BRAF,SAPK2, PTK, Abl Yes 2012 In Use
NA Relugolix Orgovyx 120mg Hormonal Therapy Androgen Receptor Inhibitor GnRH Receptor Antagonist Yes 2020 In Use
NA Ribociclib Kisqali 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
NA Ribociclib and letrozole Kisqali Femara Co-pack 200 mg/ 2.5 mg Chemotherapy, Hormonal Therapy Cyclin dependent kinase inhibitor/ aromatase inhibitor CDK 4/6 Yes 2017 In Use
NA Darolutamide Nubeqa 300mg Hormonal Therapy Androgen Receptor Inhibitor Non-Steroidal Yes 2019 In Use
NA Enzalutamide Xtandi 40 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 2012 In Use
NA Panobinostat Farydak 10 mg Chemotherapy Enzyme Inhibitor HDAC Yes 2015 In Use
NA Ruxolitinib Jakafi 10 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Uridine Triacetate Xuriden 2 g Ancillary Therapy Chemoprotective Antidote Yes 2015 In Use
NA Quizartinib Vanflyta Multiple Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2023 In Use
NA Rucaparib Rubraca 200 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.